FOXP3 demethylation as a means of identifying quantitative defects inregulatory T cells in acute coronary syndrome

Atherosclerosis

Volumn 229, Issue 1, 2013, Pages 263-270

  Lü, Cai Xia ^a   Xu, Ren De ^a,b   Cao, Ming ^a   Wang, Guan ^a   Yan, Feng Qin ^a   Shang, Sha Sha ^a   Wu, Xiao Fen ^a   Ruan, Lei ^a   Quan, Xiao Qing ^a   Zhang, Cun Tai ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Acute coronary syndrome; Atherosclerosis; DNA methylation; Forkhead box P3; Regulatory T cells; Younger ACS patients

Indexed keywords

ALPHA INTERFERON; INTERLEUKIN 10; TRANSCRIPTION FACTOR FOXP3;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CD4+ CD25+ T LYMPHOCYTE; CLINICAL EVALUATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DEMETHYLATION; DNA METHYLATION; EPIGENETICS; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE;

ACUTE CORONARY SYNDROME; ADULT; AGED; ANTIGENS, CD4; ATHEROSCLEROSIS; AZACITIDINE; BIOLOGICAL MARKERS; CELLS, CULTURED; CHOLESTEROL, LDL; DNA MODIFICATION METHYLASES; DOWN-REGULATION; FEMALE; FLOW CYTOMETRY; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-10; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; MALE; METHYLATION; MIDDLE AGED; T-LYMPHOCYTES, REGULATORY; TRANSFORMING GROWTH FACTOR BETA1; TROPONIN I; UP-REGULATION;

EID: 84879420439     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2013.05.007     Document Type: Article

References (30)

1. Lopez A.D., Mathers C.D., Ezzati M., Jamison D.T., Murray C.J. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006, 367:1747-1757.
2. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. NEngl J Med 2005, 352:1685-1695.
3. Ammirati E., Cianflone D., Vecchio V., et al. Effector memory t cells are associated with atherosclerosis in humans and animal models. JAm Heart Assoc 2012, 1:27-41.
4. Sakaguchi S. Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 2004, 22:531-562.
5. Hori S., Nomura T., Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003, 299:1057-1061.
6. Mallat Z., Gojova A., Brun V., et al. Induction of a regulatory T cell type 1 response reduces the development of atherosclerosis in apolipoprotein E-knockout mice. Circulation 2003, 108:1232-1237.
7. Ait-Oufella H., Salomon B.L., Potteaux S., et al. Natural regulatory T cells control the development of atherosclerosis in mice. Nat Med 2006, 12:178-180.
8. Mor A., Planer D., Luboshits G., et al. Role of naturally occurring CD4+ CD25+ regulatory T cells in experimental atherosclerosis. Arterioscler Thromb Vasc Biol 2007, 27:893-900.
9. Mor A., Luboshits G., Planer D., Keren G., George J. Altered status of CD4(+)CD25(+) regulatory T cells in patients with acute coronary syndromes. Eur Heart J 2006, 27:2530-2537.
10. Zhao Z., Wu Y., Cheng M., et al. Activation of Th17/Th1 and Th1, but not Th17, is associated with the acute cardiac event in patients with acute coronary syndrome. Atherosclerosis 2011, 217:518-524.
11. de Boer O.J., van der Meer J.J., Teeling P., van der Loos C.M., van der Wal A.C. Low numbers of FOXP3 positive regulatory T cells are present in all developmental stages of human atherosclerotic lesions. PLoS One 2007, 2:e779.
12. Patel S., Chung S.H., White G., Bao S., Celermajer D.S. The "atheroprotective" mediators apolipoprotein A-I and Foxp3 are over-abundant in unstable carotid plaques. Int J Cardiol 2010, 145:183-187.
13. Ammirati E., Cianflone D., Banfi M., et al. Circulating CD4+CD25hiCD127lo regulatory T-cell levels do not reflect the extent or severity of carotid and coronary atherosclerosis. Arterioscler Thromb Vasc Biol 2010, 30:1832-1841.
14. Najib E., Puranik R., Duflou J., Xia Q., Bao S. Age related inflammatory characteristics of coronary artery disease. Int J Cardiol 2012, 154:65-70.
15. Ito T., Hanabuchi S., Wang Y.H., et al. Two functional subsets of FOXP3+ regulatory T cells in human thymus and periphery. Immunity 2008, 28:870-880.
16. Wang J., Ioan-Facsinay A., van der Voort E.I., Huizinga T.W., Toes R.E. Transient expression of FOXP3 in human activated nonregulatory CD4+ T cells. Eur J Immunol 2007, 37:129-138.
17. Ziegler S.F. FOXP3: not just for regulatory T cells anymore. Eur J Immunol 2007, 37:21-23.
18. Allan S.E., Crome S.Q., Crellin N.K., et al. Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production. Int Immunol 2007, 19:345-354.
19. Zhou X., Bailey-Bucktrout S.L., Jeker L.T., et al. Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells invivo. Nat Immunol 2009, 10:1000-1007.
20. Roncador G., Brown P.J., Maestre L., et al. Analysis of FOXP3 protein expression in human CD4+CD25+ regulatory T cells at the single-cell level. Eur J Immunol 2005, 35:1681-1691.
21. Baron U., Floess S., Wieczorek G., et al. DNA demethylation in the humanFOXP3 locus discriminates regulatory T cells from activated FOXP3+ conventional T cells. Eur J Immunol 2007, 37:2378-2389.
22. Wieczorek G., Asemissen A., Model F., et al. Quantitative DNA methylation analysis of FOXP3 as a new method for counting regulatory T cells in peripheral blood and solid tissue. Cancer Res 2009, 69:599-608.
23. Zheng Q., Xu Y., Liu Y., et al. Induction of Foxp3 demethylation increases regulatory CD4+CD25+ T cells and prevents the occurrence of diabetes in mice. JMol Med (Berl) 2009, 87:1191-1205.
24. Choi J., Ritchey J., Prior J.L., et al. Invivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia. Blood 2010, 116:129-139.
25. Han S.-f., Liu P., Zhang W., et al. The opposite-direction modulation of CD4+CD25+ Tregs and T helper 1 cells in acute coronary syndromes. Clin Immunol 2007, 124:90-97.
26. Norata G.D., Pirillo A., Catapano A.L. HDLs, immunity, and atherosclerosis. Curr Opin Lipidol 2011, 22:410-416.
27. Seddiki N., Santner-Nanan B., Tangye S.G., et al. Persistence of naive CD45RA+ regulatory T cells in adult life. Blood 2006, 107:2830-2838.
28. Haas J., Fritzsching B., Trubswetter P., et al. Prevalence of newly generated naive regulatory T cells (Treg) is critical for Treg suppressive function and determines Treg dysfunction in multiple sclerosis. JImmunol 2007, 179:1322-1330.
29. Hoffmann P., Boeld T.J., Eder R., et al. Loss of FOXP3 expression in natural human CD4+CD25+ regulatory T cells upon repetitive invitro stimulation. Eur J Immunol 2009, 39:1088-1097.
30. Issa J.P. Optimizing therapy with methylation inhibitors in myelodysplastic syndromes: dose, duration, and patient selection. Nat Clin Pract Oncol 2005, 2(Suppl. 1):S24-S29.